

Medicines	Indication	Further Information	Estimated LSCMMG
Medicines prioritised for New Medicine Reviews			
Qutenza 179mg cutaneous patch (capsaicin)	Treatment of peripheral neuropathic pain in adults either alone or in combination with other medicinal products for the treatment of pain	Requested by Pain Management Consultant, Blackpool Teaching Hospitals Trust	May 2024
Liothyronine oral preparations	Treatment of resistant depression – reclassification from Do not prescribe to Amber 1	Requested by Lancashire and South Cumbria NHS Foundation Trust	June 2024
Acarizax 12 SQ-HDM oral lyophilisate	Treatment of house dust mite sensitisation according to SPC definitions, see: https://www.medicines.org.uk/emc/product/12905	Requested by ENT consultant, ELHT	June 2024
Infliximab	For treatment of chemotherapy induced colitis	Requested by Oncology Pharmacist UHMB	June 2024
Colesevelam	For CVD prevention in hyperlipidaemia when the patient is intolerant of all other options	Requested by Medicines Management, Central ICB locality	July 2024
Nefopam	Treatment of pain	Pharmacy, BTHTr	July 2024
Ivabradine	Treatment of POTS (postural orthostatic tachycardia syndrome)	Cardiologist, BTHTr	September 2024
GoResp digihaler (budesonide/formoterol)	For treatment of asthma and COPD	Requested by Medicines Management, Fylde Coast	September 2024

Medicine on hold, awaiting licensing or additional information

Infliximab increased dosing	Treatment of ulcerative colitis and Crohn's disease	Requested by ELHT. Awaiting pathway discussions before proceeding.	TBC
-----------------------------	---	---	-----